表紙
市場調査レポート

世界の血友病市場の分析

Global Hemophilia Market Report: 2016 Edition

発行 Koncept Analytics 商品コード 246749
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
世界の血友病市場の分析 Global Hemophilia Market Report: 2016 Edition
出版日: 2016年04月11日 ページ情報: 英文 52 Pages
概要

当レポートでは、世界における血友病治療関連市場の最新動向について分析し、市場の特徴や全体的構造、治療法開発の最新状況、市場の促進要因と今後の課題、競争環境、主要企業のプロファイルと事業戦略などを調査すると共に、今後の市場動向を推計しています。

第1章 血友病:概要

  • 血友病の種類
  • 兆候
  • 治療法

第2章 市場概況

  • 世界の血友病市場
    • 有病率
    • 診断および治療
    • 市場収益
    • 血友病A向け血液凝固タンパク質第VIII因子(FVIII)需要
    • 遺伝子組換え第VIII因子の供給能力
    • 血友病Aの市場収益
    • 血友病Bの市場収益
    • 血友病インヒビター市場収益
  • 米国市場
    • 治療を受けた患者数(年間)
    • 市場収益
    • 治療を受けた血友病A患者数(年間)
    • 血友病A市場収益
    • 治療を受けた血友病A患者数(年間)
    • 治療を受けた血友病B患者数(年間)
    • 血友病B市場収益
    • 血友病インヒビター治療患者数(年間)
    • 血友病インヒビター市場収益
    • ヴォン・ヴィレブランド因子市場収益
  • 欧州市場
    • 患者数
    • 血友病A患者数
    • 血友病A治療:重症度別
    • 血友病B患者数
    • 血友病B治療:重症度別

第3章 市場のダイナミクス

  • 成長促進要因
    • 遺伝子組み換え型第VIII因子の普及
    • 医療費支出の増加
    • 低所得国における治療法の新たな活用法
    • 診断率の増加
  • 主要動向
    • 予防へのシフト
    • 遺伝子療法
    • 半減期が長い製品の導入
  • 課題
    • 治療の高コスト
    • 新たな治療法・製品への切り替え抵抗

第4章 競合情勢

  • 市場シェア別
  • 財務状況別

第5章 企業のプロファイル

  • Shire PLC
    • 事業概要
    • 主な財務指標
    • 事業戦略
  • Bayer Group
  • Novo Nordisk
  • Pfizer, Inc.

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Hemophilia refers to a set of hereditary genetic disorders that impairs the body's ability to control blood clotting, which controls bleeding when a blood vessel is broken. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. In the absence of a treatment, uncontrolled internal bleeding can occur, causing stiffness, pain, severe joint damage and even death. Depending upon the coagulation factor deficiency, there are different types of hemophilia such as Hemophilia A, Hemophilia B, Hemophilia C, Von Willebrand disease and Hemophilia with Inhibitors.

Even though Hemophilia is rare bleeding disorder, the number of people affected by it has been increasing with time. While mild hemophilia is easy to diagnose especially in kids, when they learn to move and walk, and get large bruises from minute falls, severe hemophilia patients need to go for periodic transfusion of the respective factors so as to avoid the event of life-threatening bleeding episodes. Such a periodic transfusion is done through what is commonly known as the replacement therapy. With increasing sophistication and modernization of technology, demand for advanced treatment options increases, thereby making the entire market grow.

The key factors which are anticipated to drive this market include increasing penetration of recombinant factor VIII, increasing healthcare expenditure, emerging use of treatments in low income countries and increasing diagnosis rates. Some of the noteworthy progresses of this industry include the increasing adoption of prophylaxis therapy, introduction of extended half-life products and gene therapy. However, the growth of respective industry is challenged by the high cost of treatments and high reluctance by patients to switch to new treatments/products.

The report provides a comprehensive study of global hemophilia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global hemophilia industry is highly competitive consisting of several large companies including the Shire Plc, Bayer Group, Pfizer Inc, Novo Nordisk etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Table of Contents

1. Overview

  • 1.1 Types of Hemophilia
    • 1.1.1 Hemophilia A
    • 1.1.2 Hemophilia B
    • 1.1.3 Hemophilia C
    • 1.1.4 Hemophilia with Inhibitors
    • 1.1.5 Von Willebrands Disease
  • 1.2 Signs and Symptoms
  • 1.3 Treatments of Hemophilia
    • 1.3.1 Replacement Therapy

2. Market Analysis

  • 2.1 Global Hemophilia Market
    • 2.1.1 Global Hemophilia Prevalence
    • 2.1.2 Global Hemophilia Diagnosis and Treatment
    • 2.1.3 Global Hemophilia Market Revenue
    • 2.1.4 Global Demand for FVIII for Hemophilia A
    • 2.1.5 Global Supply Capacity of Recombinant FVIII for Hemophilia
    • 2.1.6 Global Hemophilia A Market Revenue
    • 2.1.7 Global Hemophilia B Market Revenue
    • 2.1.8 Global Hemophilia with Inhibitors Market Revenue
  • 2.2 The US Hemophilia Market
    • 2.2.1The US Hemophilia Patients Treated per Year
    • 2.2.2 The US Hemophilia Market Revenue
    • 2.2.3 The US Hemophilia A Patients Treated per Year
    • 2.2.4 The US Hemophilia A Market Revenue
    • 2.2.5 The US Hemophilia B Patients Treated per Year
    • 2.2.6 The US Hemophilia B Market Revenue
    • 2.2.7 The US Hemophilia with Inhibitors Patients Treated per Year
    • 2.2.8 The US Hemophilia with Inhibitors Market Revenue
    • 2.2.9 The US Von Willebrand Factor Market Revenue
  • 2.3 Europe Hemophilia Market
    • 2.3.1 Europe Hemophilia Patients
    • 2.3.2 Europe Hemophilia A Patients
    • 2.3.3 Europe Hemophilia A Therapy by Severity
    • 2.3.4 Europe Hemophilia B Patients
    • 2.3.5 Europe Hemophilia B Therapy by Severity

3. Market Dynamics

  • 3.1 Growth Drivers
    • 3.1.1 Increasing Penetration of Recombinant FVIII
    • 3.1.2 Increasing Healthcare Expenditures
    • 3.1.3 Emerging Use of Treatments in Low Income Countries
    • 3.1.4 Increasing Diagnosis Rate
  • 3.2 Key Trends
    • 3.2.1 Increasing adoption of Prophylaxis
    • 3.2.2 Gene Therapy
    • 3.2.3 Introduction of Extended Half-Life Products
  • 3.3 Challenges
    • 3.3.1 High Cost of Treatment
    • 3.3.2 Reluctance to Switch to New Treatments/Products

4. Competitive Landscape

  • 4.1 Competition by Market Share
    • 4.1.1 Hemophilia Market Share
    • 4.1.2 Hemophilia A Market Share
  • 4.2 Competition by Financials
    • 4.2.1 Competition by Market Cap
    • 4.2.2 Competition by Profit Margin

5. Company Profiles

  • 5.1 Shire PLC
    • 5.1.1 Business Overview
    • 5.1.2 Financial Overview
    • 5.1.3 Business Strategies
  • 5.2 Bayer Group
    • 5.2.1 Business Overview
    • 5.2.2 Financial Overview
    • 5.2.3 Business Strategies
  • 5.3 Novo Nordisk
    • 5.3.1 Business Overview
    • 5.3.2 Financial Overview
    • 5.3.3 Business Strategies
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Financial Overview
    • 5.4.3 Business Strategies

List of Charts

  • Types of Hemophilia
  • Global Hemophilia Prevalence (2015)
  • Global Hemophilia Diagnosis and Treatment Ratio (2015)
  • Global Hemophilia Market Revenue (2015E-2020F)
  • Global Hemophilia Revenue Share by Category (2015E)
  • Global Hemophilia Revenue Share by Category -Forecast (2020)
  • Global FVIII Demand by Volume (2011-2015E)
  • Global FVIII Demand by Category - Volume (2015E-2017E)
  • Global Supply Capacity of Recombinant FVIII - Actual (2011-2015E)
  • Global Supply Capacity of Recombinant FVIII - Forecast (2016F-2017F)
  • Global Hemophilia A Market Revenue (2015E-2020F)
  • Global Hemophilia A Revenue Share by Category (2015E)
  • Global Hemophilia B Market Revenue (2015E-2020F)
  • Global Hemophilia with Inhibitors Market Revenue (2015E-2020F)
  • The US Hemophilia Patients Treated per Year (2013-2020F)
  • The US Hemophilia Market Revenue (2013-2015E)
  • The US Hemophilia Market Revenue - Forecast (2016F-2020F)
  • The US Hemophilia A Patients Treated per Year (2013-2020F)
  • The US Hemophilia A Market Revenue (2013-2020F)
  • The US Hemophilia B Patients Treated per Year (2013-2020F)
  • The US Hemophilia B Market Revenue (2013-2020F)
  • The US Hemophilia with Inhibitors Patients Treated per Year (2013-2020F)
  • The US Hemophilia with Inhibitors Market Revenue (2013-2020F)
  • The US Von Willebrand Factor Market Revenue (2013-2020F)
  • Europe Hemophilia Patients (2014-2020F)
  • Europe Hemophilia A Patients (2014-2020F)
  • Europe Hemophilia A Patients by Severity (2015E)
  • Europe Hemophilia A Therapy by Severity (2015E)
  • Europe Hemophilia B Patients (2015E-2020F)
  • Europe Hemophilia B Patients by Severity (2015E)
  • Europe Hemophilia B Therapy by Severity (2015E)
  • Penetration of Recombinant FVIII (2014)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global Per Capita Usage of FVIII by Income Groups (2014)
  • Prophylaxis Therapy Usage by Category (2015E)
  • Global Hemophilia Market Share (2015E)
  • Global Hemophilia A Market Share (2015E)
  • Market Capitalization Comparison (2015)
  • Gross Profit Margin Comparison (2015)
  • Revenue Share by Product Category, Shire PLC (2015)
  • Revenue and Net Income, Shire PLC (2011-2015)
  • Revenue Share by Business Segments, Bayer Group (2015)
  • Revenue and Net Income, BAYER (2011-2015)
  • Revenue Share by Business Segments, Novo Nordisk (2015)
  • Revenue and Net Income, Novo Nordisk (2011-2015)
  • Revenue Share by Business Segments, Pfizer Inc. (2015)
  • Revenue and Net Income, Pfizer (2011-2015)

List of Tables

  • Gene Therapy Products under Development (2015)
  • Extended Half-Life Products under Development (2015)
Back to Top